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Abstract
Background: Public health strategies are needed to curb antimalarial drug resistance. Theoretical argument
points to an association between malaria transmission and drug resistance although field evidence remains limited.
Field observations, made in Zimbabwe, on the relationship between transmission and multigenic drug resistance,
typified by chloroquine, are reported here.
Methods: Periodic assessments of the therapeutic response of uncomplicated falciparum malaria to chloroquine
in two selectively sprayed or unsprayed health centre catchments, from 1995 – 2003. Cross-sectional analysis of
in vivo chloroquine failure events for five sites in relation to natural endemicity and spraying history.
Results: During selective house spraying, the chloroquine failure rate for the sprayed catchment decreased, such
that, after four years, the odds of chloroquine failure were 4× lower than before start of spraying in the area (OR
0.2, 95% CI 0.07 – 0.75, p = 0.010, n = 100). Chloroquine failure odds for the sprayed area became 4× lower than
contemporaneous failure odds for the unsprayed area (OR 0.2 95% CI 0.08 – 0.65, p = 0.003, n = 156), although
the likelihood of failure was not significantly different for the two catchments before selective spraying started
(OR 0.5, 95% CI 0.21 – 1.32; p = 0.170, n = 88). When spraying ended, in 1999, the drug failure odds for the
former sprayed area increased back 4 fold by 2003 (OR 4.2, 95%CI 1.49 – 11.78, p = 0.004, n = 146). High altitude
areas with naturally lower transmission exhibited a 6× lower likelihood of drug failure than low-lying areas (OR
0.16 95% CI 0.068 – 0.353, -2 log likelihood change 23.239, p < 0.001, n = 465). Compared to sites under ongoing
annual spraying, areas that were last sprayed 3–7 years ago experienced a 4-fold higher probability of chloroquine
failure (OR 4.1, 95%CI 1.84 – 9.14, -2 log likelihood change 13.956, p < 0.001).
Conclusion:  Reduced transmission is associated with suppressed levels of resistance to chloroquine and
presumably other regimens with multigenic drug resistance. It seems the adoption of transmission control
alongside combination chemotherapy is a potent strategy for the future containment of drug-resistant malaria.
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Background
The escalation of parasite drug resistance has persisted as
a major obstacle to malaria control for decades [1-3].
Owing to dwindling options for affordable, safe and effec-
tive drugs, rising clinical failure rates exact a substantial
public health toll, especially in Africa [4,5]. In countries
that recently replaced chloroquine with sulfadoxine/
pyrimethamine as first line treatment, there are signs of
increasing resistance to the antifolate combination [1,2,6-
9]. Partly because of the spectre of drug resistance, phar-
maceutical companies reduced investment in new anti-
malarial drug research. Fortunately, official calls in the
mid 1990's led to renewed public-private sector initiatives
for the development of new compounds, as well as the
improvement of existing ones [10,11].
However, Plasmodium falciparum has repeatedly demon-
strated the ability to develop resistance to practically any
drug upon wider introduction, as illustrated by multi-
drug resistance, especially in South East Asia [12-15].
Thus, public health strategies that delay or minimize the
escalation of drug resistance are urgently required. To
date, the only approach that has been widely evaluated
and is currently being introduced is the use of combina-
tion chemotherapy [11,16,17] which protects constituent
drugs from resistance through a multigenic mechanism of
resistance and strategic pharmacological properties such
as short half-life. In poor countries the effectiveness of this
method is hampered by increased cost of medication. Fur-
thermore, even the new combinations are not totally pro-
tected from the development of resistance, as illustrated
by the recent confirmations of clinical failure and in vitro
resistance to proguanil/atovaquone [18-22]. Additional
strategies are, therefore, needed to ensure the successful
containment of drug-resistant malaria.
Mathematical models have been proposed suggesting a
relationship between malaria transmission and the evolu-
tion of drug resistance, though some workers suggest a
positive association [23,24] while others propose a nega-
tive one [25,26]. Major implications for control pertain to
this question. It may mean that vector control pro-
grammes are counterproductive by aggravating drug
resistance, or, it could be that they complement chemo-
therapy by alleviating resistance. Although this interaction
between transmission and drug resistance is further
addressed in a review [27], the exact answer still remains
uncertain against a background of limited field evidence.
The present paper presents observations on the field rela-
tionship between transmission variations (both natural
and vector control induced) and the levels of in vivo mul-
tigenic drug resistance, typified by chloroquine.
Methods
Study areas and population
Zimbabwe, on the southern fringes of malaria in Africa,
experiences seasonal and potentially epidemic transmis-
sion characterized by a non-immune population with
high probability of drug treatment [28-30]. The country
has sustained a national malaria vector control pro-
gramme for decades, based on intradomicilliary applica-
tion of residual insecticide. From the early 1990s selective
vector control was introduced, in which areas with mod-
erate transmission are of less priority and spraying is
focused in zones of high transmission/high malarial inci-
dence. Chloroquine has remained the first line treatment
for uncomplicated malaria, although a combination of
chloroquine and sulfadoxine/pyrimethmanine is cur-
rently being introduced in some areas. A tiered drug distri-
bution policy has been implemented in the country, so
that, until 1997, chloroquine was the only antimalarial
available at the peripheral level. Thereafter, policy revi-
sions allowed wider distribution of sulfadoxine/
pyrimethamine to treat chloroquine failure cases.
The study was based at five health centres located in the
low-lying (<600 m above sea level) hyperendemic trans-
mission zone as well as those in the higher altitude (600
– 1200 m asl) mesoendemic transmission zone bordering
the malaria-free central watershed (Table 1, Fig 1). All the
study locations experience seasonal, single peak (Febru-
ary-May) malaria transmission typical for Zimbabwe.
Acute symptoms and complications occur across all ages
in this non-immune population, where asymptomatic
carriage of asexual parasitaemia is rare [28,29]. The study
was conducted on uncomplicated falciparum malaria
cases of all age groups presenting at the health centres for
treatment.
Table 1: Study area characteristics
Site Elevation Endemicity *Population Estimate Villages of patient origin Spraying status Treatment drug
Burma Valley 683 m mesoendemic 11764 25 Last sprayed 1999 CQ+S/P since 2001
Chitakatira 1211 m mesoendemic 13245 28 Last sprayed 1998 CQ+S/P since 2003
Sahumani 784 m mesoendemic 5950 24 Last sprayed 1992 CQ+S/P since 2003
Madhuku 471 m hyperendemic 11583 39 Ongoing CQ+S/P since 2001
Mola ≈500 m hyperendemic 13000 28 Ongoing CQ+SP since 2001
*2002–2003 population census.Malaria Journal 2004, 3:35 http://www.malariajournal.com/content/3/1/35
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Study design
The study was a prospective assessment of the therapeutic
response of P. falciparum malaria to chloroquine from
1995–2003. Consecutive assessments of therapeutic
response were conducted in two mesoendemic sites dur-
ing the presence or absence of selective indoor residual
insecticide spraying (house spraying). Transverse assays
for Pfmdr1 and Pfcrt mutations associated with chloro-
quine resistance were carried out in these two sites during
the 1998–99 transmission season. Further assessments of
in vivo chloroquine therapeutic response were carried out
cross-sectionally in another three sites where treatment
change to chloroquine (CQ) + sulfadoxine/pyrimeth-
amine (SP) was not yet being implemented due to tempo-
rary unavailability of SP. Malarial incidence was
determined retrospectively for all sites using available
health centre records.
In vivo antimalarial therapeutic efficacy assessments
The  in vivo therapeutic efficacy of chloroquine was
assessed using the standard WHO (1996) protocol [31].
Since this protocol was primarily targeted for regions of
intense malaria transmission, two modifications were
adopted to suit the seasonal/epidemic conditions of Zim-
babwe. These were (i) inclusion of febrile patients of all
age groups and (ii) adoption of radical asexual parasite
elimination as a criterion for adequate response to
treatment.
Inclusion of all age groups was on the rationale that there
is no premunition in the population. Recruited patients
were thus a representative sample of the symptomatic
population which presents for treatment with chloro-
quine in the primary health care system. The radical asex-
ual parasite elimination criterion was adopted because
persistent asexual parasitaemia poses a risk of complica-
tions in non-immunes.
Molecular detection of Pfmdr1 and Pfcrt polymorphisms
Amino acid polymorphisms at codons 86 and 1246 of the
P. falciparum Pfmdr1 gene and at codon 76 of the P. falci-
parum  chloroquine resistance transporter gene (Pfcrt),
which are associated with chloroquine resistance [32,33],
were detected by PCR and codon-specific restriction
enzyme digestion [34,35]. Appropriate positive and nega-
tive control strains were used in interpretation and, except
for the Pfcrt  codon, additional restriction sites were
included in the target PCR product to serve as internal
controls for complete digestion.
Ethics
The study was approved by respective provincial medical
health authorities and by the Medical Research Council of
Zimbabwe. Patient participation was by the informed
consent of the patients themselves or guardians, in the
case of children.
Location of study sites, shown in relation to altitudinal zones  that govern malaria endemicity Figure 1
Location of study sites, shown in relation to altitudinal zones 
that govern malaria endemicity. Central watershed (elevation 
> 1200 m above sea level) experiences nil – hypoendemic 
malaria transmission, and endemicity increases with falling 
altitude towards the north and south of the country.
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Monthly malarial incidence in Burma valley (BV) and Sahum- ani (SH) catchments during and after selective spraying  (boxed terms, Risk Ratios (95% CI) for peak malaria trans- mission period (February – May)) Figure 2
Monthly malarial incidence in Burma valley (BV) and Sahum-
ani (SH) catchments during and after selective spraying 
(boxed terms, Risk Ratios (95% CI) for peak malaria trans-
mission period (February – May)).
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Results
Association of house-spraying with reduced levels of 
chloroquine resistance
(i) Burma Valley and Sahumani follow-up study
On the grounds of low malarial incidence, the catchments
of Sahumani clinic, in Mutasa district and Burma Valley
clinic, in Mutare district (Fig 1), were removed from the
spraying programme in 1992, with the advent of selective
control to save on inseciticide. However, the Burma catch-
ment, which is situated on commercial farms, was re-allo-
cated to annual spraying from 1995 – 1999 when, for
economic reasons, local farmers agreed to supply the
malaria control authorities with insecticide. The Burma
catchment subsequently reverted to no spraying after the
1999 spraying operation, due to disagreements between
commercial farmers and the government. In contrast, the
Sahumani catchment, which is located in villages,
remained unsprayed from 1992.
There were no malaria statistics for the two health centres
prior to 1998, (1997 for Sahumani). However, during the
selective annual spraying, the risk of contracting malaria
in the sprayed Burma Valley catchment was at least 2.6
fold lower than for Sahumani (Fig 2) from 1998 – 2000.
After the selective spraying operation ended in 1999, the
malarial incidence became uniform for the two catch-
ments by 2001 (Fig 2).
Table 2: Chloroquine therapeutic failure (TF) rates in Sahumani and Burma Valley from 1995–2003.
Therapeutic failure rate (n)
1995 1997/98* 1999 2003
Burma Valley 27.0% (37) 15.2% (33) 7.9% (93) 26.5% (83)
Sahumani 41.2% (51) 30.3% (33) 26.9% (65) -
Odds ratio (95% CI) 1.89 (0.76 – 4.72) 2.4 (0.73 – 8.14) 4.3 (1.54 – 11.85) -
P 0.170 0.142 0.003 -
*Burma Valley 1997 compared to Sahumani 1998.
Table 3: Relative abundance of mutated P. falciparum genotypes in Sahumani and Burma Valley (1998 and 1999 transmission seasons).
Mutant genotype OR (95%CI) of mutants (Sahumani : Burma Valley) P N
Pfmdr1 Tyr-86 2.4 (1.2 – 4.7) 0.013 137
Pfmdr1 Tyr-1246 4.2 (1.7 – 10.7) 0.001 135
Pfcrt Thr-76 2.2 (1.1 – 4.6) 0.028 144
Pfmdr1 Tyr-86 + Pfmdr1 Tyr-1246 3.9 (1.5 – 10.1) 0.003 132
Pfmdr1 Tyr-86 + Pfmdr1 Tyr-1246 + Pfcrt Thr-76 4.0 (1.6 – 10.3) 0.002 131
Distribution of mutated (m) and wild (w) P. falciparum vari- ants in Burma Valley (BV) and Sahumani (SH), at Pfmdr1  codons 86 (Pfmdr-86) and 1246 (Pfmdr-1246), and Pfcrt  codon 76 (Pfcrt-76) Figure 3
Distribution of mutated (m) and wild (w) P. falciparum vari-
ants in Burma Valley (BV) and Sahumani (SH), at Pfmdr1 
codons 86 (Pfmdr-86) and 1246 (Pfmdr-1246), and Pfcrt 
codon 76 (Pfcrt-76).
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The therapeutic failure rate of Burma Valley decreased
during selective spraying (Table 2) such that by 1999, the
odds of chloroquine failure were 4× lower than they were
before spraying resumed in this area (OR (95% CI) 0.233
(0.072 – 0.747), for 1999 compared to 1995; 0.482
(0.270 – 0.861), for each year of spraying: -2 log
likelihood ratio change 6.432, df = 1, p = 0.011). Thera-
peutic failure rates were not significantly different in the
Burma Valley and Sahumani catchments (1995 season)
prior to selective spraying of Burma Valley (Table 2).
However, by 1999 the odds of drug failure had become 4×
lower in the annually sprayed Burma catchment (Table 2).
The failure rate in Sahumani did not significantly change
during the 4-year period (OR (95%CI): 0.62 (0.25 –
1.57), for 1998 compared to 1995; 0.53 (0.26 – 1.08) for
1999 compared to 1995; 0.85 (0.71 – 1.02) for each suc-
cessive year, -2 × log likelihood ratio change, 3.080, df, 1,
p = 0.0793).
After selective spraying ceased in 1999, the odds of drug
failure in Burma valley increased back 4-fold by 2003 (OR
(95%): 4.18 (1.485 – 11.782), p = 0.004, n = 146) Chlo-
roquine efficacy assessments for 2003 were not conducted
in Sahumani as the treatment was changed that year to
chloroquine plus sulfadoxine/pyrimethamine.
(ii) In vivo prevalence of mutations in Pfmdr1 and Pfcrt genes
Amino acid polymorphisms on Pfmdr1 and Pfcrt codons
associated with chloroquine resistance were examined in
pre-treatment patient samples from 1998 and 1999 in
Burma Valley and Sahumani (i.e. 3–4 years after re-start of
spraying in Burma Valley). Resistance-associated muta-
tions at amino acid codons 86 and 1246 of Pfmdr1, and
codon 76 of Pfcrt, were more prevalent in the Sahumani
area (Table 3, Fig 3). Interestingly, mixed infections con-
taining both mutant and wild type variants tended to be
more frequent in the Burma Valley area (Fig 3), despite
lower transmission in this catchment. The same distribu-
tion pattern observed with individual codons was mir-
rored in mutated haplotypes comprising two or more
amino acid codons (Table 3). Three-codon haplotypes
from the sprayed area exhibited significantly more mixed
mutant and wild variants at one or more codons than
corresponding haplotypes from the unsprayed area (odds
ratio 5.4, 95 % CI: 1.89 – 15.54, p = 0.001, n = 131).
Drug failure as a function of transmission
A scatterplot of chloroquine therapeutic failure rate with
malarial incidence suggested a positive association (Fig
4). In stead of using parametric tests on arcsine
transformed data (perhaps better done with more data
points), the probability of chloroquine failure was exam-
ined as a function of transmission zone, and spraying his-
tory, using a logistic model. The health centre catchments
naturally falling in the mesoendemic zone according to
altitudinal classifications [28], did exhibit significantly
lower malarial incidence, for at least the previous 10 years,
than those in the hyperendemic zone (Fig 5, Table 4). In
the logistic regression, the probability of therapeutic fail-
ure was 6.4-fold lower in these mesoendemic catchments
than in hyperendemic ones (Table 5, 6, 7). At any time
point, catchments that were under ongoing annual spray-
ing experienced 4-fold lower likelihood of drug failure
than those that were last sprayed 3–7 years ago (Table 5).
Discussion
The build up of drug-resistant P. falciparum malaria calls
for public health strategies to maximize the useful life of
antimalarials. According to the findings of the present
study, reduced transmission, due to vector control or high
altitude, was associated with suppressed levels of in vivo
therapeutic failure and genotypic resistance to chloro-
quine. Assuming that chloroquine resistance has a multi-
genic mechanism, as is the general consensus [12,36,37],
this association between transmission and drug resistance
presumably governs other drugs or drug combinations
that have polygenically encoded resistance.
From the Burma Valley and Sahumani cross-sectional
assays, there was, in the sprayed catchment, a higher like-
lihood of infections carrying mixed mutated and wild
type codons, for both Pfcrt and Pfmdr1, despite the lower
Scatter plot of therapeutic failure prevalence with malarial  incidence Figure 4
Scatter plot of therapeutic failure prevalence with malarial 
incidence.
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transmission. This paradoxical result suggests that the
sprayed area probably favoured more genetic out-cross-
ing, resulting in recombination break down of drug-resist-
ant haplotypes. The genetic out-crossing may partly
explain the association of low drug resistance with the
house spraying. Further studies are needed to verify this
relationship in more areas.
In Burma Valley, despite drug pressure, the proportion of
resistant parasites decreased during spraying, and subse-
quently resurged after the spraying stopped. This is remi-
niscent of the decrease in proportion of chloroquine-
resistant parasites reported in China [38], and more
recently in Malawi [39,40], following suspension of chlo-
roquine use. From these observations it would seem that
chloroquine-resistant parasites bear a fitness cost as drug
selection advantage is removed or counteracted.
What is distinct about the current results is that the fitness
cost for resistance appeared to occur in the sporogonic
phase, as distinguished from an in vivo fitness burden that
is thought to ensue following cessation of drug use. In the
Monthly malarial incidence per thousand population in hyperendemic (hyper) and mesoendemic (meso) catchments Figure 5
Monthly malarial incidence per thousand population in hyperendemic (hyper) and mesoendemic (meso) catchments.
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Table 4: Risk of clinically diagnosed malaria in hyperendemic and mesoendemic catchments during the peak malaria season (February 
– May).
Year 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Hyperendemic 
population 
(elev. <600 m)
21306 21925 22643 34298 35733 27647 25578 22651 27174 27989
Mesoendemic 
population 
(elev. ≥600 m)
65664 66497 69788 75761 88181 90910 93721 48244 96057 61625
Malarial RR 
(95% CI)
1.9 (1.72 – 
1.99)
1.7 (1.57 – 
1.81)
5.3 (5.09 – 
5.55)
2.8 (2.67 – 
2.88)
1.1 (1.09 – 
1.17)
5.0 (4.82 – 
5.12)
2.0 (1.89 – 
2.04)
2.7 (2.56 – 
2.75)
1.6 (1.55 – 
1.69)
3.3 (3.06 – 
3.48)
P <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Table 5: The probability of chloroquine therapeutic failure as a function of transmission level and spraying history
: Independent variable coding
Parameter coding
(1) (2) (3) (4)
Study year 2003 1.000 .000 .000 .000
1999 .000 1.000 .000 .000
1998 .000 .000 1.000 .000
1997 .000 .000 .000 1.000
1995 .000 .000 .000 .000
Last annual spraying 3+ yrs ago 1.000
0 yrs/ongoing .000
Transmission level mesoendemic 1.000
hyperendemic .000
Table 6: The probability of chloroquine therapeutic failiure as a function of transmission level and spraying history: variables in the 
equation
B S.E. Wald df Sig. *Exp(B) 95.0% C.I. for EXP(B)
Lower Upper
Step 1(a) Transmission level (1) -1.863 0.419 19.780 1 0.000 0.155 0.068 0.353
Last annual spraying (1) 1.411 0.409 11.879 1 0.001 4.099 1.838 9.142
Study year 13.037 4 0.011
Study year (1) -0.728 0.290 6.317 1 0.012 0.483 0.274 0.852
Study year (2) -0.400 0.317 1.589 1 0.207 0.671 0.360 1.248
Study year (3) -0.224 0.440 0.259 1 0.611 0.799 0.338 1.892
Study year (4) 0.262 0.445 0.346 1 0.556 1.299 0.543 3.109
Constant -0.157 0.407 0.149 1 0.700 0.855
a Variable(s) entered on step 1: Transmission, Last annual spraying, Study year.
* corresponds to odds ratio for therapeutic failureMalaria Journal 2004, 3:35 http://www.malariajournal.com/content/3/1/35
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present results, drug selection advantage for the resistant
parasites appeared to be directly counteracted by inde-
pendent survival limiting factors, such as vector control
and high altitude. This has important implications for
control as it means that drug-resistant P. falciparum can be
contained during drug use. Furthermore, costly acquisi-
tion of immunity in the resident population is, presuma-
bly, not the only prerequisite for curbing drug resistance.
The present results afford field evidence supporting the
continuation of sustainable malaria vector control pro-
grammes. Similar findings were reported for Uganda [41],
although the same workers found a difference between
chloroquine (multigenic resistance) and sulfadoxine/
pyrimethamine (monogenic resistance) below a critical
threshold of transmission [37]. These papers may further
support the findings of the present study. It has been cau-
tioned that resistance might exacerbate as eradication is
approached [42]. However, in the current study, the low
transmission levels associated with high altitude and
spraying showed no signs of this counterproductive effect.
Moreover, in poor countries, which are the de facto strong-
hold for malaria, eradication so far remains only an aca-
demic prospect, as the malaria burden continues to
increase [43]. It seems that the adoption of sustainable
transmission control with combination chemotherapy is
a potent approach for the future containment of drug-
resistant malaria.
Conclusions
Reduced transmission due to house spraying or high alti-
tude is associated with suppressed levels of phenotypic
and genotypic resistance to chloroquine and presumably
other multigenically encoded drug regimens. Transmis-
sion control implemented with combination
chemotherapy seems a potent approach for the future
containment of drug-resistant malaria.
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